Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

JAK inhibitors: a home run for GVHD patients?

Teshima T.

Blood. 2014 Jun 12;123(24):3691-3. doi: 10.1182/blood-2014-04-570325. No abstract available.

2.

Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.

Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T, Verbeek M, Fischer J, Otten V, Schmickl M, Maas-Bauer K, Finke J, Peschel C, Duyster J, Poeck H, Zeiser R, von Bubnoff N.

Blood. 2014 Jun 12;123(24):3832-42. doi: 10.1182/blood-2013-12-543736. Epub 2014 Apr 7.

3.

Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms.

Tefferi A.

N Engl J Med. 2012 Mar 1;366(9):844-6. doi: 10.1056/NEJMe1115119. No abstract available.

PMID:
22375977
4.

Janus activated kinase inhibition in myelofibrosis.

Malhotra H.

Indian J Cancer. 2012 Jul-Sep;49(3):260-5. doi: 10.4103/0019-509X.104482. Review.

5.

Ruxolitinib for myelofibrosis.

Haznedaroglu IC.

N Engl J Med. 2012 May 24;366(21):2032; author reply 2032-5. doi: 10.1056/NEJMc1203704#SA3. No abstract available.

PMID:
22621635
6.

Ruxolitinib for myelofibrosis.

Koschmieder S, Koppelle A, Seifert H.

N Engl J Med. 2012 May 24;366(21):2031-2; author reply 2032-4. doi: 10.1056/NEJMc1203704#SA2. No abstract available.

PMID:
22621634
7.

Ruxolitinib for myelofibrosis.

Diamantidis MD.

N Engl J Med. 2012 May 24;366(21):2031; author reply 2032-4. doi: 10.1056/NEJMc1203704#SA1. No abstract available.

PMID:
22621633
8.

JAK inhibition: the key to treating myeloproliferative neoplasm?

Tibes R, Bogenberger JM, Mesa RA.

Expert Rev Hematol. 2012 Dec;5(6):583-5. doi: 10.1586/ehm.12.55. No abstract available.

PMID:
23216589
9.

The different faces of Janus kinase inhibition.

Vandenberghe P.

Haematologica. 2012 Apr;97(4):475. doi: 10.3324/haematol.2012.066449. No abstract available.

10.

JAK2 inhibitors in myelofibrosis.

Pardanani A.

Clin Adv Hematol Oncol. 2011 Nov;9(11):856-8. No abstract available.

PMID:
22252617
11.

Deal watch: dipping into Incyte's JAK-pot.

[No authors listed]

Nat Rev Drug Discov. 2010 Feb;9(2):94. doi: 10.1038/nrd3113. No abstract available.

PMID:
20118954
12.

Ruxolitinib Benefits Some with Pancreatic Cancer.

[No authors listed]

Cancer Discov. 2015 Dec;5(12):1231. doi: 10.1158/2159-8290.CD-NB2015-142. Epub 2015 Oct 13.

13.

Targeting myeloproliferative neoplasms with JAK inhibitors.

Pardanani A, Tefferi A.

Curr Opin Hematol. 2011 Mar;18(2):105-10. doi: 10.1097/MOH.0b013e3283439964. Review.

PMID:
21245760
14.

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G.

N Engl J Med. 2012 Mar 1;366(9):787-98. doi: 10.1056/NEJMoa1110556.

15.

New generation small-molecule inhibitors in myeloproliferative neoplasms.

Passamonti F, Maffioli M, Caramazza D.

Curr Opin Hematol. 2012 Mar;19(2):117-23. doi: 10.1097/MOH.0b013e32834ff575. Review.

PMID:
22227528
16.

Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis.

Gisslinger H, Schalling M, Gisslinger B, Skrabs C, Müllauer L, Kralovics R.

Am J Hematol. 2014 Mar;89(3):344-6. doi: 10.1002/ajh.23637. No abstract available.

17.

JAK inhibition in myelofibrosis.

Arellano-Rodrigo E, Alvarez-Larrán A.

N Engl J Med. 2010 Dec 16;363(25):2464; author reply 2464-5; discussion 2465. doi: 10.1056/NEJMc1011635#SA1. No abstract available.

PMID:
21158663
18.

Balancing efficacy and safety of JAK inhibitors in myelofibrosis.

Passamonti F.

Leuk Res. 2014 Mar;38(3):290-1. doi: 10.1016/j.leukres.2013.12.022. Epub 2014 Jan 4. No abstract available.

PMID:
24444869
19.

[Treatment of chronic graft-versus-host disease with protein tyrosine kinase inhibitors].

Martínez C.

Methods Find Exp Clin Pharmacol. 2010 Dec;32 Suppl A:69-71. Review. Spanish.

PMID:
21381292
20.

Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.

de Masson A, Bouaziz JD, Peffault de Latour R, Wittnebel S, Ribaud P, Rubio MT, Micol JB, Suarez F, Nguyen S, Dalle JH, Yakouben K, Robin M, Xhaard A, Adès L, Bourhis JH, Rybojad M, Bagot M, Socié G.

Blood. 2012 Dec 13;120(25):5089-90. doi: 10.1182/blood-2012-09-453928. No abstract available.

Supplemental Content

Support Center